Abstract
The pandemic triggered by coronavirus disease (COVID-19) invariably questions the health security of people around the globe. It’s also strongly advocates the need for unique health care practice that substantially prevents the infection and practice of controlling the disease transmission. Alternate therapy with viable medications that can adequately strengthen the immune system to enhance the speedy recovery of the patients becomes the need of the hour. Siddha system of medicine is one such versatile practice that emerged before centuries that incorporates the practice of availing potential remedies from herbal and another natural origin. Still, now there is no proper documentary evidence on evaluating the efficacy of Siddha treatment in the clinical management of COVID-19, hence the main objective of the present pilot study is to investigate the potential of Siddha formulations such as Aadathodai kudineer, Thaalisaathi chooranam, Thulasi chooranam, Pavala parpam, Bramaanandha Bairava Maathirai and Thoothuvalai nei in treatment and accelerating the recovery of COVID19 patients. A Study was executed in 25 patients with laboratory- confirmed diagnosis of COVID-19. The Outcome of the present clinical study signifies that treatment with Siddha medicines significantly accelerated recovery of patients by stabilising the immune mechanism which was evidenced by pronouncing declination in CRP (C- reactive protein), neutrophil, lymphocytes, Lactate dehydrogenase (LDH), Creatinine, Serum Albumin and Serum Urea level almost back to the normal. In conclusion therapy with Siddha medicines opened a new gateway in the clinical practice on managing COVID-19 due presence of vital phytotherapeutics that showcase multiple pharmacological activities against risky pathogens like SARS-CoV-2.
Highlights
The emergence of SARS-CoV-2 viral infection have been first-ever reported at the Wuhan wet market of china in Dec 2019 and has later attained the name COVID-19 in following the nomenclature issued by WHO in Feb 2020 [1]
Age and gender play a significant role in predicting the susceptibility of an individual towards COVID-19
Numerous researches finding strongly supports the fact that an increase in age proportionally increases the chances of attaining SARS-CoV-2 infection
Summary
The emergence of SARS-CoV-2 viral infection have been first-ever reported at the Wuhan wet market of china in Dec 2019 and has later attained the name COVID-19 in following the nomenclature issued by WHO in Feb 2020 [1]. SARS-CoV-2 virus reveals spectacular dynamism in wide spread transmission between Jan to July 2020 and sweeping its wing to date. More than 98 million cases were found positive for corona infection and over 21 lakhs reported deaths globally until 27 January 2021(2). A biological sequence of infectivity begins with the interaction between the viral spike proteins with that of the ACE2 receptors (angiotensin-converting enzyme). Group of specialised protease enzymes greatly supports the entry, fusion and release mechanism of the viral genomic component in to the host cellular environment [3].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
